Literature DB >> 22966785

Limitations of encapsidation of recombinant self-complementary adeno-associated viral genomes in different serotype capsids and their quantitation.

Yuan Wang1, Chen Ling, Liujiang Song, Lina Wang, George V Aslanidi, Mengqun Tan, Changquan Ling, Arun Srivastava.   

Abstract

We previously reported that self-complementary adeno-associated virus (scAAV) type 2 genomes of up to 3.3 kb can be successfully encapsidated into AAV2 serotype capsids. Here we report that such oversized AAV2 genomes fail to undergo packaging in other AAV serotype capsids, such as AAV1, AAV3, AAV6, and AAV8, as determined by Southern blot analyses of the vector genomes, although hybridization signals on quantitative DNA slot-blots could still be obtained. Recently, it has been reported that quantitative real-time PCR assays may result in substantial differences in determining titers of scAAV vectors depending on the distance between the primer sets and the terminal hairpin structure in the scAAV genomes. We also observed that the vector titers determined by the standard DNA slot-blot assays were highly dependent on the specific probe being used, with probes hybridizing to the ends of viral genomes being significantly overrepresented compared with the probes hybridizing close to the middle of the viral genomes. These differences among various probes were not observed using Southern blot assays. This overestimation of titer is a systemic error during scAAV genome quantification, regardless of viral genome sequences and capsid serotypes. Furthermore, different serotypes capsid and modification of capsid sequence may affect the ability of packaging intact, full-length AAV genomes. Although the discrepancy is modest with wild-type serotype capsid and short viral genomes, the measured titer could be as much as fivefold different with capsid mutant vectors and large genomes. Thus, based on our data, we suggest that Southern blot analyses should be performed routinely to more accurately determine the titers of recombinant AAV vectors. At the very least, the use of probes/primers hybridizing close to the mutant inverted terminal repeat in scAAV genomes is recommended to avoid possible overestimation of vector titers.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22966785      PMCID: PMC4015078          DOI: 10.1089/hgtb.2012.090

Source DB:  PubMed          Journal:  Hum Gene Ther Methods        ISSN: 1946-6536            Impact factor:   2.396


  44 in total

1.  Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration.

Authors:  C L Halbert; T A Standaert; M L Aitken; I E Alexander; D W Russell; A D Miller
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

3.  Quantitative DNA slot blot analysis: inhibition of DNA binding to membranes by magnesium ions.

Authors:  D M Kube; A Srivastava
Journal:  Nucleic Acids Res       Date:  1997-08-15       Impact factor: 16.971

4.  Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus.

Authors:  D Duan; Y Yue; Z Yan; J Yang; J F Engelhardt
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

5.  Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression.

Authors:  R J Samulski; L S Chang; T Shenk
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

6.  Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors.

Authors:  Ziying Yan; Roman Zak; G W Gant Luxton; Teresa C Ritchie; Ursula Bantel-Schaal; John F Engelhardt
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

7.  Quantification of adeno-associated virus particles and empty capsids by optical density measurement.

Authors:  Jürg M Sommer; Peter H Smith; Sumathy Parthasarathy; Jesse Isaacs; Sharmila Vijay; Jane Kieran; Sharon K Powell; Alan McClelland; J Fraser Wright
Journal:  Mol Ther       Date:  2003-01       Impact factor: 11.454

8.  Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype.

Authors:  Rita Sarkar; Renee Tetreault; Guangping Gao; Lili Wang; Peter Bell; Randy Chandler; James M Wilson; Haig H Kazazian
Journal:  Blood       Date:  2003-10-09       Impact factor: 22.113

9.  Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation.

Authors:  A M Douar; K Poulard; D Stockholm; O Danos
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

10.  Growth of human hepatoma cells lines with differentiated functions in chemically defined medium.

Authors:  H Nakabayashi; K Taketa; K Miyano; T Yamane; J Sato
Journal:  Cancer Res       Date:  1982-09       Impact factor: 12.701

View more
  22 in total

1.  Productive life cycle of adeno-associated virus serotype 2 in the complete absence of a conventional polyadenylation signal.

Authors:  Lina Wang; Zifei Yin; Yuan Wang; Yuan Lu; Daniel Zhang; Arun Srivastava; Changquan Ling; George V Aslanidi; Chen Ling
Journal:  J Gen Virol       Date:  2015-06-30       Impact factor: 3.891

2.  Split AAV-Mediated Gene Therapy Restores Ureagenesis in a Murine Model of Carbamoyl Phosphate Synthetase 1 Deficiency.

Authors:  Matthew Nitzahn; Gabriella Allegri; Suhail Khoja; Brian Truong; Georgios Makris; Johannes Häberle; Gerald S Lipshutz
Journal:  Mol Ther       Date:  2020-04-17       Impact factor: 11.454

3.  Absolute determination of single-stranded and self-complementary adeno-associated viral vector genome titers by droplet digital PCR.

Authors:  Martin Lock; Mauricio R Alvira; Shu-Jen Chen; James M Wilson
Journal:  Hum Gene Ther Methods       Date:  2014-02-14       Impact factor: 2.396

4.  Efficient central nervous system AAVrh10-mediated intrathecal gene transfer in adult and neonate rats.

Authors:  J Hordeaux; L Dubreil; J Deniaud; F Iacobelli; S Moreau; M Ledevin; C Le Guiner; V Blouin; J Le Duff; A Mendes-Madeira; F Rolling; Y Cherel; P Moullier; M-A Colle
Journal:  Gene Ther       Date:  2015-01-15       Impact factor: 5.250

5.  Efficient CNS targeting in adult mice by intrathecal infusion of single-stranded AAV9-GFP for gene therapy of neurological disorders.

Authors:  K Bey; C Ciron; L Dubreil; J Deniaud; M Ledevin; J Cristini; V Blouin; P Aubourg; M-A Colle
Journal:  Gene Ther       Date:  2017-04-20       Impact factor: 5.250

6.  Adeno-Associated Virus Vector Mobilization, Risk Versus Reality.

Authors:  Liujiang Song; R Jude Samulski; Matthew L Hirsch
Journal:  Hum Gene Ther       Date:  2020-10       Impact factor: 5.695

7.  Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice.

Authors:  Sofia Benkhelifa-Ziyyat; Aurore Besse; Marianne Roda; Sandra Duque; Stéphanie Astord; Romain Carcenac; Thibaut Marais; Martine Barkats
Journal:  Mol Ther       Date:  2013-01-08       Impact factor: 11.454

8.  The hepatocyte-specific HNF4α/miR-122 pathway contributes to iron overload-mediated hepatic inflammation.

Authors:  Min Li; Yuxiao Tang; Lusha Wu; Fengfeng Mo; Xin Wang; Hongxia Li; Ruirui Qi; Hongwei Zhang; Arun Srivastava; Chen Ling
Journal:  Blood       Date:  2017-06-27       Impact factor: 22.113

9.  Direct Head-to-Head Evaluation of Recombinant Adeno-associated Viral Vectors Manufactured in Human versus Insect Cells.

Authors:  Oleksandr Kondratov; Damien Marsic; Sean M Crosson; Hector R Mendez-Gomez; Oleksandr Moskalenko; Mario Mietzsch; Regine Heilbronn; Jonathan R Allison; Kari B Green; Mavis Agbandje-McKenna; Sergei Zolotukhin
Journal:  Mol Ther       Date:  2017-08-10       Impact factor: 11.454

10.  Systemic delivery of tyrosine-mutant AAV vectors results in robust transduction of neurons in adult mice.

Authors:  Asako Iida; Naomi Takino; Hitomi Miyauchi; Kuniko Shimazaki; Shin-ichi Muramatsu
Journal:  Biomed Res Int       Date:  2013-05-20       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.